Corona virus disease 2019 (COVID-19) is a new, rapidly spreading infectious disease of the human respiratory system. It is caused by a recently dis-covered enveloped RNA β corona virus called severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) (Lu et al., 2020). SARSCoV2 is the seventh known coronavirus that infects humans. The coro-navirus has contributed to previous epidemics such as SARS-CoV and MERS-CoV. In December 2019after a case study of indicators related to the fishery goods and wet animal whole-sale market in Wuhan, Hubei Province, China, it extended to more than 200 coun-tries (Callaway et al., 2020). As of 09:21 UTC on 28 July 2021, there are 195,368,552 cases that have been confirmed and 4,178,287 deaths in almost 200 coun-tries/territories and 26 cruise/naval ships (Mallapaty, 2020).

Patients with existing companion illnesses, especially CVD, are at high risk of serious illness. COVID-19 can cause terrifying pulmonary complications such as acute respiratory distress syndrome, as well as acute myocardial damage and dysfunction, which can promote or contribute to shock and manifold organ failure. In this study, the effects of COVID 19 on the CV system are divided into primary or secondary cardiac invasion. Arrhythmias, acute coronary syn-drome (ACS), and myocarditis are the most common cardiac symptoms of COVID19 illness. Secondary cardiac invasion is commonly caused by systemic inflammatory syndrome and may be manifested in acute myocardial damage/ elevated biomarkers and / or heart failure (CHF). Secondary cardiac interven-tion often includes other evidence of visceral damage. Finally, additional vascular complications of COVID-19 disease are identified and described (Dan et al., 2020).

Strategy Searching - According to the pre-deter-mined protocol a systematic literature search was conducted in PubMed, Google Scholar, SCOPUS databases from 1st July, 2021 to 1st August, 2021. Symptoms of COVID-19, heart disease, COVID-19 fatalities, cardiovascular abnormalities, and myocar-dial injury, causes of myocardial infarction, arrhy-thmia, and acute coronary syndrome were search terms for the literature searching function (Long et al., 2020). We didnt look for preprints on websites since several experts were concerned about the quality of some articles before they went through a rigorous peer-review procedure (Impact of Social Sciences, 2020).

Study Selection - Six reviewers did the literature search and exported the papers that were found to be eligible. The literature was screened based on the desired outcome. Approximately 55 articles were pri-marily retrieved a total of 36 articles were selected that fulfilled the stated review criteria for inclusion. All conflicts were resolved by all the reviewers.

Data Information - Our review covered trials that involved patients who were at least 18 years old. The major outcome of interest was cardiovascular com-plications with severe COVID-19, which was defined as all-cause death, ICU hospitalization, ARDS, or mechanical ventilation requirement. Pre-existing CVD and its conventional risk variables identified in major CVD clinical guidelines like age, sex, smoking, hypertension, dyslipidemia, and diabetes were all potential risk factors of interest (Karmali and Lloyd Jones, 2017).

Data Extraction - Full-text papers were checked and the following data was extracted like year of pub-lication, study date, sample size of COVID-19 pati-ents, number of participants with each co morbidity who died and did not die, cardiovascular compli-cations in case of Covid-19 patients, the mean or median age, as well as their standard deviations and the pro-portion of men in each study.

Data Synthesis and Analysis - The number of studies, study settings, proportion of sex, means or median age, and variables accounted for in each research were all described using a narrative method. The risk of death in COVID-19 individuals with pre-existing cardiovascular illnesses was our primary outcome. However, reviewers visually evaluated for the likelihood of publication bias, and heterogeneity of study estimates was assessed to maintain the possibility of significant heterogeneity (Sentongo et al., 2020).

COVID-19 and cardiovascular disease - COVID-19s influence on the cardiovascular system will be split into main and secondary cardiac involvement in this review; there is, of course, a lot of overlap bet-ween the two. Arrhythmias, ACS, and myocarditis are the primary cardiac symptoms of COVID-19 illness. A systemic inflammatory condition can cause second-dary cardiac involvement, which can appear as acute myocardial damage, biomarker increase, and/or heart failure (CHF). Other signs of end-organ dam-age are frequently seen with secondary cardiac involvement.

Primary Cardiac Involvement 

Arrhythmias - COVID-19 has been shown to have both tacky- and brady-arrhythmias. Research that looked at the clinical characteristics and prognosis of 138 Chinese patients with COVID-19 found that 16.7% of them had arrhythmia (Wang et al., 2020). Additionally, patients receiving hydroxy-chloroquine treatment should consider the warnings listed below-(1) dosage decrease for individuals with severe renal insufficiency (50 percent for creatinine clearance 10 mL/min), (2) vigorous electrolyte correction prior to usage, and (3) avoidance or cautious monitoring for patients with hereditary long QT or those taking several QT prolonging medicines (Ayad et al., 2010; Chen et al., 2020). The high rate of hypokalemia in COVID-19 patients may, at least in part, increase the risk of arrhythmia (Chen et al., 2020). SARS-CoV-2 infects cells via attaching to ACE2 receptors, which increases angiotensin II availability and therefore increases urine potassium excretion (Chen et al., 2020). 

Acute Coronary Syndrome (ACS) - ACS is more common in the presence of a virus, most likely owing to plaque instability caused by inflammation. Al-though the risk of COVID-19 infection is unclear, other viruses have been linked to a three- to tenfold increase in risk (BOYLE, 1997; Naghavi et al., 2003; Gattone et al., 2001). In the midst of the global crisis, several healthcare facilities in Europe, North Ame-rica, and Asia have reexamined their processes for treating ACS, taking into account the potential dangers of healthcare worker exposure and the usage of personal protective equipment. In a case series from New York, 18 COVID-19 patients with STEMI on ECG were investigated; 6 (33%) of these patients reported chest pain, 14 (78%) had localized ST-seg-ment elevation, 6 (35%) had a regional wall motion abnormality on TTE, and 8 (44%) had a clinical diagnosis of myocardial infarction (Bangalore et al., 2020). A total of 9 (50%) individuals had coronary angiography, with 6 (67%) of them showing obstruct-tive disease (Bangalore et al., 2020). Infection control and management are two additional factors that may influence the therapeutic approach and therapy of ACS in patients with COVID-19 (Nahid, 2021). 

Myocarditis - COVID-19 acute myocarditis has an unclear actual prevalence. Although few occurrences of clinically diagnosed myocarditis have been docu-mented in COVID-19 individuals, the number of autopsy and endomyocardial biopsy (EMB) confir-med cases is low. One case from Italy revealed widespread myocardial edema and EMB on cardio-vascular magnetic resonance imaging (CMR), as well as diffuse T-lymphocytic inflammatory infiltrates (Sala et al., 2020). SARS-CoV-2 was found in car-diac macrophages but not cardiomyocytes in another instance, according to an EMB (Mihic et al., 2015). These findings support the hypothesis that myo-carditis is a source of cardiac damage in COVID-19 patients, although the exact mechanism of myo-carditis remains unclear. EMB and CMR have little value in the treatment of these individuals. Multiple antiviral (e.g., remdesivir, ribavirin, lopinavir, hydro-xylchloroquine) and anti-inflammatory (e.g., inter-feron, corticosteroids, tocilizumab, sarilumab, siltu-ximab, anakinra, intravenous immunoglobulin, statin) treatments are being investigated to help us manage COVID-19 myocarditis patients (Zhou et al., 2020). Hydroxychloroquine in a well-designed retrospective study, 9 more recently has shown poor efficacy for the treatment of COVID-19 disease (Porfidia et al., 2021).

Secondary Cardiac Involvement 

Acute Myocardial Injury - The most prevalent CV consequence in COVID-19 is acute myocardial in-farction.  Acute myocardial damage has been defined differently in different studies, such as an increase in cardiac enzymes or electrocardiographic abnormal-lities. In COVID-19 disease, the etiology of acute myocardial damage is likely complex, with many overlapping path-ways (Mihic et al., 2015). Acute myocardial dam-age has been observed in around a quarter of hospitalized patients, with greater cardiac troponin levels indicating a more serious condition (Zhou et al., 2020; Guo et al., 2020, Lippi, Lavie and Sanchis-Gomar, 2020). One retrospective research found that COVID-19 non-survivors had fast trop-onin increase late in their course, indicating that a local troponin test, in addition to CRP, D-dimer, and NT-proBNP, may be utilized to follow clinical pro-gress (Zhou et al., 2020). Acute cardiac dam-age has regularly been demonstrated to be a powerful un-favorable prognostic marker in patients with COVID-19 (Wang et al., 2020; Huang et al., 2020), regardless of the actual frequency. However acute plaque rupture and viral invasion are another two mecha-nisms that cause direct myocardial damage. Accor-ding to recent histopathology evidence COVID-19 endotheliitis is caused by direct endothelial viral invasion with diffuse endothelial inflammation (Varga et al., 2020). This Endotheliitis is known to cause tissue inflammation and organ ischemia by impairing microcirculatory activity (Bonetti et al., 2003). Furthermore, in the setting of COVID-19 infect-ion, individuals without prior cardiac illness have presented with mainly cardiac symptoms, reflecting a potential clinical picture of myocarditis (Hu et al., 2020; Karmpaliotis et al., 2007). The infla-mmatory reaction and cytokine storm seen in severe COVID-19 illness may exacerbate myocardial stress and damage. This can affect heart function indirectly via peripheral effects on systemic vascular resistance (Pelliccia et al., 2017).

Heart Failure - Heart failure can happen due to myo-cardial injury, and chronic stable heart failure is liable to worsen during COVID-19 infection. It is not un-usual for people with COVID-19 illness to have new heart failure (HF). Heart failure was identified as a problem in 23% of patients in a retrospective study from Wuhan, China (52% of non-survivors) (Zhou et al., 2020). Heart failure in COVID-19 patients can range from mild heart failure with a normal ejection fraction early on in the disease to severe heart failure with a reduced ejection fraction later on in the illness to severe end-stage heart failure and cardiogenic shock with a high mortality risk. Patients with under-lying heart failure have an increased risk of mortality and morbidity (Porfidia et al., 2021; Mehra and Ruschitzka, 2020). The actual cause of COVID-19s ventricular failure is unknown. In individuals with AR-DS, higher levels of serum brain natriuretic pep-tide (BNP) have been related to cardiogenic pulmo-nary edema (Karmpaliotis et al., 2007). Surprisingly, people with COVID-19 might have elevated BNP levels even if they dont have any ventricular dys-function (Zhou et al., 2020). Nonetheless, increased cardiac biomarkers, especially troponin, should pro-mpt clinical suspicion of heart failure. However, be-cause there are numerous causes of heart damage, interpreting cardiac biomarkers can be difficult. If heart failure is suspected, a restricted TTE or POCUS can measure biventricular function.

Treatment

ACEIs/ARBs/Angiotensin Receptor-Neprilysin In-hibitor (ARNIs) - Patients with heart failure and a decreased ejection fraction, independent of COVID-19 infection, should be treated with an angiotensin converting enzyme inhibitor or angiotensin receptor blocker while being closely monitored (Porfidia et al., 2021). Because sacubitril concentration rises in par-allel with ritonavir administration, its critical to keep track of blood pressure, serum creatinine, and pota-ssium levels in patients on sacubitril/valsartan.

Beta-Blockers - Patients with ACS, with the excep-tion of those with hemodynamic instability and pul-monary edema, and those with heart failure with a decreased ejection fraction, should be treated with a beta-blocker. Carvedilol is metabolized via glucuro-nicdation (UGT1A1) and CYP450, metoprolol is processed mostly by CYP2D6, and bisoprolol is par-tly metabolized by CYP3A4 and CYP2D6 (Giguère et al., 2019). As a result, ritonavir can alter the meta-bolism of all of these drugs, which is why patients on lopinavir/ritonavir should have their heart rate and blood pressure closely monitored.

Diuretics - Loop diuretics and anti-COVID medi-cines have no known interactions, thus they can be started or sustained safely in individuals with CO-VID-19. Because these groups of patients have a significant risk of acute renal damage, diuretic medi-cation should be continuously evaluated in terms of vital signs, serum electrolytes, and creatinine. Min-eral-ocorticoid antagonists can be continued in indivi-duals with COVID 19 provided they are given under strict supervision.

Digoxin - Because of the risk of instability during an acute infection, all patients on digoxin who are hospitalized with COVID-19 should be closely watc-hed. This may demand serum concentration mea-surements in COVID-19 patients who continue to take digoxin. Furthermore, ritonavir can enhance the AUC and half-life of digoxin by 29% and 43%, res-pectively. Hydroxychloroquine can also raise digoxin levels through an unidentified mechanism (Dixon et al., 2020).

Hydralazine/Nitrates - Protease inhibitors can lower the amount of nitric oxide produced by isosorbide dinitrate, reducing its effectiveness. Protease inhi-bitors and hydralazine have a strong interaction. Dose modifications should be made based on the patients reaction (Giguère et al., 2019).

Ivabradine - Despite a maximum acceptable dose of beta-blockers, patients with ejection fractions of 35 per-cent or below, sinus rhythms, and minimal resting heart rates of 70 beats per minute are treated with ivabradine, and I(f) channel blocker. Ivabradine appears to be safe to continue in COVID-19 indi-viduals who are hemodynamically stable. Ivabradines AUC can be increased by six-fold when combined with strong CYP450 inhibitors; therefore, it should be avoided in patients taking lopinavir/ritonavir for COVID-19 (Lippi et al., 2020).

Principal findings - In this systematic review, we focus on the link between severe COVID-19 and CVD and its associated risk factors. The findings of this systematic review show that patients with pre-existing cardio-vascular illness, hypertension, con-gestive heart failure, chronic renal disease, and patients who are hospitalized with COVID-19 have a higher risk of mortality from COVID-19. In studies that controlled for age and a few other co-morbidities, one very large research found independent correla-tions of hypertension with severe COVID-19 (Liang et al., 2020). The independence of these relationships from significant confounders, notably age, is a key concern. However, the observed correlations of hy-pertension and diabetes with the severity of COVID-19 infection should not be interpreted as evidence of renin-angiotensin system inhibitor side effects. Fur-thermore, in the sole research that looked at the prevalence of renin-angiotensin system inhibitor usage (Cheng et al., 2020), 30% of patients had hypertension, but only 5% of them were using renin-angiotensin system inhibitors (Cheng et al., 2020). As a result, several expert groups advice continuing to use this class of medications until further data be-comes available (South et al., 2020).

Consequences for clinical practice and research -

Our findings support the concept that people who appear to be at higher risk should be given vaccine first to develop immunization against SARS-CoV-2.Individuals with pre-existing cardiovascular illness, hypertension, diabetes, congestive heart failure, chro-nic renal disease, and cancer are at a higher risk of mortality from the virus and should be given first priority when a vaccine is distributed, especially if supplies are limited. Individuals with pre-existing cardiovascular illness, hypertension, diabetes, con-gestive heart failure, chronic renal disease, and cancer are at a higher risk of mortality from the virus and should be given first priority when a vaccine is distributed, especially if supplies are limited. SARS-CoV-2 may become seasonal, necessitating yearly immunization, according to mounting data (Mori-yama et al., 2020; Islam et al, 2021).

Strength - Our systematic review offers a number of advantages: a comprehensive assessment of CVD and its risk factors, clinically appropriate criteria of severe COVID-19 that reduce subjective reporting, and care-ful consideration of probable patient overlap using restricted and inclusive meta-analyses. Meta-reg-ression was used to investigate possible con-foun-ding, and the period between the literature search and paper submission was only 3 weeks.

Limitations of the study

The first constraint is that the bulk of researches were undertaken in China because the pandemic started there. But we must have to recognize the geogra-phical differences in some risk variables, and addi-tional research in many locations (Wang et al., 2019). Secondly, we did not include non-English public-cations and so overlooked several important studies. Thirdly the majority of research used odds ratios, which are known to overestimate risk ratios when exposure prevalence is high. Finally, its impossible to rule out the likelihood that some patients were included in several researches, particularly the China CDC report and other Chinese investigations (Liu et al., 2020). 

COVID-19s widespread distribution has wreaked havoc on peoples health all over the world. COVID-19 is now recognized to cause cardio-vascular problems, and persons with underlying cardiovascular disease are more vulnerable to infection. As this new epidemic unfolds, a number of cardiac symptoms are becoming apparent. Its important to note that in the post-pandemic age, cardiovascular problems will still be the primary cause of mortality. At this time, there is unquestionably a dearth of information on the cardiovascular implications, thus more study is needed to identify the safest drug regimen for CO-VID-19 patients. In order to avoid or effectively manage COVID-19 infection-related consequences, patients with hypertension should be monitored on a regular basis. Clinicians should be aware of the known cardiac involvement and address it at the onset to minimize harm until a vaccine or potentially curative treatment is available. We will need a longer-term follow-up of severe COVID-19 patient survivors due to the increasing recognition of CVD damage in this disease. In addition, we need to be aware of the negative effects and drug interactions that now exist.

First and foremost, the author is grateful to Almighty Allah. The author is also thankful to anonymous reviewers and editors for their supportive comments and suggestions.

The authors declare that they have no competing interests.